Peer Exchange

Experience With Biologics and Pathways
March 01, 2019 – 
Panelists share their personal experiences with biologics and the benefit of pathways.
Severe Patients and Final Thoughts
March 01, 2019 – 
Experts provide final thoughts on treatment and asthma.

 
IL-5–Inhibiting Agents Mepolizumab, Benralizumab, and Reslizumab
February 22, 2019 – 
Experts review the IL-5–inhibiting agents mepolizumab, benralizumab, and reslizumab.
 
Dupilumab: Mechanism, Dosing, and Pivotal Trials
February 22, 2019 – 
Experts provide an overview of dupilumab, including mechanism of action, dosing, and pivotal trials.
 
Adherence With CDK4/6 Inhibitors
February 19, 2019 – 
Kate Jeffers, PharmD, sums up the importance of patient adherence with CDK4/6 inhibitors and quality metrics used to measure adherence.
Uncontrolled Severe Asthma and Difference among Biologics
February 15, 2019 – 
Define unmanaged/uncontrolled severe asthma and provide an overview of the available biologics.
Omalizumab: Adverse effects, Mechanism, and Patient Factors
February 15, 2019 – 
A review of Omalizumab’s adverse effects, mechanism, and ideal patient factors.
 
Patient Management of CDK4/6 Inhibitors
February 12, 2019 – 
Important touchpoints for patient management of CDK4/6 inhibitors.
Dispensing of CDK4/6 Inhibitors
February 12, 2019 – 
Outlining different dispensing options for CDK4/6 inhibitors including in-clinic, specialty, and medically integrated dispensing.
Biomarkers–Diagnostic Tool for Optimal Therapy
February 08, 2019 – 
A discussion on the biomarkers used to determine efficacy with specific biologics.
 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.